Literaturverzeichnis

Allen, J.D., Brinkhuis, R.F., Wijnholds, J., Schinkel, A.H. (1999). The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59 (17), 4237-4241.

Allikmets, R., Schriml, L.M., Hutchinson, A., Romano-Spica, V., Dean, M. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (23), 5337-5339.

Amarzguioui, M., Brede, G., Babaie, E., Grotli, M., Sproat, B., and Prydz, H. (2000). Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res. 28 (21), 4113-4124.

Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I., Gottesman, M.M. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 361-398.

Augustine, L.M., Markelewicz, R.J., Boekelheide, K., Cherrington, N.J. (2005). Xenobiotic and endobiotic transporters mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33 (1), 182-189.

Bassi, G.S., Murchie, A.I.H., Lilley, D.M.J. (1996). The ion-induced folding of the hammerhead ribozyme: Core sequence changes that perturb folding into the active conformation. RNA. 2 (8), 756-768.

Bassi, G.S., Murchie, A.I.H., Walter, F., Clegg, R.M., Lilley, D.M.J. (1997). Ion-induced folding of the hammerhead ribozyme: A fluorescence resonance energy transfer study. EMBO J. 16 (24), 7481-7489.

Bellon, S.F., Coleman, J.H., and Lippard, S.J. (1991). DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 30 (32), 8026-8035.

Benderra, Z., Trussardi, A., Morjani, H., Villa, A.M., Doglia, S.M., Manfait, M. (2000). Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF-7 cells overexpression multidrug resistance associated protein. Eur. J. Cancer. 36 (3), 428-434.

Berger, W., Elbling, L., Micksche, M. (2000). Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int. J. Cancer. 88 (2), 293-300.

Bertrand, E., Castanotto, D., Zhou, C., Carbonelle, C., Lee, N.S., Good, P., Chatterjee, S., Grange, T., Pictet, R., Kohn, D., Engelke, D., Rossi, J.J. (1997). The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA. 3 (1), 75-88.

Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance -associated proteins. J. Natl. Cancer Inst. 92 (16), 1295-1302.

Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A.H., Schellens, J.H. (2005). The effect of Bcrp1 (Abcg2)on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-gp inhibitors to enable the brain penetration of imatinib in patients.. Cancer Res.. 65 (7), 2577-2582.

Buzayan, J.M., Gerlach, W.L., and Bruening, G. (1986). Non-enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA. Nature. 323 (6086), 349-353.

Cech, T.R., Zaug, A. J., and Grabowski, P.J. (1981). In vitro splicing of the ribosomal RNA precursor of Tetrahymnea thermophilus: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell. 27 (3 Pt 2), 487-496.

Chaney, S.G. and Vaisman, A. (1999). Specificity of platinum-DNA adduct repair.. J. Inorg. Biochem. 77 (1-2), 71-81.

Chen, C. J., Banerjea, A. C., Harmison, G. G., Haglund, K., and Schubert, M. (1992). Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication: potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20 (17), 4581-4589.

Chen, C.-J., Banerjea, A.C., Harmison, G.G., Haglund, K., Schubert, M. (1992). Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20 (17), 4581-4589.

Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M., Roninson, I.B. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 47 (3), 381-389.

Childs, S., Yeh, R.L., Hui, D., Ling, V. (1998). Taxol resistance mediated by transfection of the liver-specific sister of P-glycoprotein. Cancer Res. 58 (18), 4160-4167.

Chin, K.V., Pastan, I., Gottesman, M.M. (1993). Function and regulation of the human multidrug resistance gene.. Adv. Cancer Res.. 60 157-180.

Cui, Y., Konig, J., Buchholz, J.K., Spring, H., Leier, I. and Keppler, D. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells.. Mol. Pharmacol.. 55 (5), 929-937.

Dahm, S.C., Uhlenbeck, O.C. (1991). Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry. 30 (39), 9464-9469.

Dean, M., Hamon, Y., and Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily.. J. Lipid Res. 42 (7), 1007-1017.

Dean, N.M. and Bennett, C.F. (2003). Antisense oligonucleotide-based therapeutics for cancer. Oncogene. 22 (56), 9087-9096.

den Boer, M.L., Pieters, R., Kazemier, K.M., Janka-Schaub, G.E., Henze, G., Veerman, A.J. (1999). Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia. 13 (12), 2023-2030.

Dias, N. and Stein, C.A. (2002). Antisense oligonucleotides: Basic concepts and mechanisms. Mol. Cancer. Ther. 1. (5), 347-355.

Dietel, M., Arps, H., Lage, H., Niendorf, A. (1990). Membrane vesicle formation due to aquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50 (18), 6100-6106.

Ding, Y. and Lawrence, C. E. (2001). Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Res. 29 (5), 1034-1046.

Ding, Y. and Lawrence, C. E. (2003). A statistical sampling algorithm for RNA secondary structure prediction.. Nucleic Acids Res. 31 (24), 7280-7301.

Ding, Y., Chan, C. Y., and Lawrence, C. E. (2004). Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res.. 32 Web Server issue, W135-W141.

Ding, Y., Chan, C.Y., Lawrence, C.E. (2004). Sfold web server for statistical folding and rational design of nucleic acids.. Nucleic Acids Res. 32 Web Server issue, W135-41.

Doudna, J.A. and (2002). The chemical repertoire of natural ribozymes. Nature. 418 (6894), 222-228.

Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., Ross, D.D. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA . 95 (26), 5665-5670.

Dubin, I.N. and Johnson, F.B. (1954). Chronic idiopathic jaundice with unidentified pigment in liver cells, a new clinicopathologic entity with a report of 12 cases.. Medicine. 33 (3), 155-197.

Durand, R.E., Olive, P.L. (2001). Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell. Biol. 64 211-233.

Earnshaw, D.J. and Gait, M.J. (1998). Hairpin ribozyme cleavage catalyzed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions.. Nucleic Acid Res. 26. (24), 5551-5561.

Eastman, A. (1987). Glutathione-mediated activation of anticancer platinum (IV) complexes. Pharmacol. Ther. 36 (23), 4177-4178.

Ee, P.L.R., He, X., Ross, D.D., Beck, W.T. (2004). Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol. Cancer Ther.. 3 (12), 1577-1583.

Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411 (6836), 494-498.

Eva, A., Robbins, K.C., Andersen, P.R., Srinivasan, A., Tronick, S.R., Reddy, E.P., Ellmore, N.W., Galen, A.T., Lautenberger, J.T., Papas, T.S., Westin, E.H., Wong-Staal, F., Gallo, R.C., Aaronson, S.T. (1982). Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature. 295 (5845), 116-119.

Fedor, M.J., Uhlenbeck, O.C. (1992). Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry. 31 (48), 13040-13045.

Fire, A., Xu, S.Q., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature. 391 (6669), 806-811.

Forster, A.C. and Symons, R.H. (1987). Self-cleavage of virosoid RNA is performed by the proposed 55-nucleotide active side. Cell. 50. (1), 9-16.

Gewirtz, D.A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 57 (7), 727-741.

Giles, R.V. (2000). Antisense oligonucleotide technology: from EST to therapeutics. Curr. Opin. Mol. Ther. 2. (3), 238-252.

Goldstein, L.J., Galski, H., Fojo, A., Willingham, M., Lai, S.L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G.M., et al. (1989). Expression of the multidrug resistance gene in human cancers. J Natl Cancer Inst. 81. (2), 116-124.

Goodchild, J. (2000). Hammerhead ribozymes: Biochemical and chemical considerations. Curr. Opin. Mol. Ther. 2 (3), 272-281.

Goodchild, J. (2004). Oligonucleotide therapeutics: 25 years agrowing. Curr. Opin. Mol. Ther. 6. (2), 120-128.

Goodchild, J. and Kohli, V. (1991). Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch. Biochem. Biophys. 284 (2), 386-391.

Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 615-627.

Gottesman, M.M. and Ambudkar, S.V. (2001). Overview: ABC transporters and human disease. J. Bioernerg. Biomembr. 33 (6), 453-458.

Green, S.K., Frankel, A., Kerbel, R.S. (1999). Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 14 (2), 153-168.

Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., and Altman, S. (1983). The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 35 (3 Pt 2), 849-857.

Gyorffy, B., Surowiak, P., Kiesslich, O., Denkert, C., Schafer, R., Dietel, M., Lage, H. (2005). Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer.

Haber, D.A., Beverley, S.M., Kiely, M.L., Schimke, R.T. (1981). Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J. Biol. Chem.. 256 (18), 9501-9510.

Harker, W.G., Slade, D.L., Drake, F.H., Parr, R.L. (1991). Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry. 30 (41), 9953-9961.

Haseloff, J and Gerlach, W.L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities.. Nature. 334. (6183), 585-591.

Heidenreich, O. and Eckstein, F. (1992). Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J. Biol. Chem. 267 (3), 1904-1909.

Hendry, P., McCall, M.J. (1995). A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes. Nucleic Acids Res. 23 (19), 3928-3936.

Hertel, K.J., Herschlag, D., Uhlenbeck, O.C. (1994). A kinetic and thermodynamic framework for the hammerhead ribozyme reaction.. Biochemistry. 33 (11), 3374-3385.

Hertel, K.J., Pardi, A., Uhlenbeck, O.C., Koizumi, M., Ohtsuka, E., Uesugi, S., Cedergren, R., Eckstein, F., Gerlach, W.L., Hodgson, R, Symons, R.H. (1992). Numbering system for the hammerhead. Nucl Acids Res. 20 (12), 3252.

Holm, P.S., Dietel, M., and Krupp, G. (1995). Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene. 167 (1-2), 221-225.

Holm, P.S., Scanlon, K.J., and Dietel, M. (1994). Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer. 70 (2), 239-243.

Hormes, R., Homann, M., Oelze, I., Marschall, P., Tabler, M., Eckstein, F., and Sczakiel, G. (1997). The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res. 25 (4), 769-775.

Hutchins, C.J., Rathjen, P.D., Forster, A.C., Symons, R.H. (1986). Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucl. Acids Res. 14 (9), 3627-3640.

Izquierdo, M.A., Neefjes, J.J., Mathari, A.E., Flens, M.J., Scheffer, G.L., Scheper, R.J. (1996). Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br. J. Cancer. 74 (12), 1961-1967.

Jain, R.K. (2001). Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46 (1-3), 149-168.

James, H.A. and Gibson, I. (1998). The therapeutic potential of ribozymes. Blood. 91 (2), 371-382.

Jenkins, J.R., Ayton, P., Jones, T., Davies, S.L., Simmons, D.L., Harris, A.L., Sheer, D., Hickson, H. (1992). Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res. 20 (21), 5587-5592.

Jonker, J.W., Merino, G., Musters, S., van Herwaarden, A.E., Bolscher, E., Wagenaar, E., Mesman, E., Dale, T.C., Schinkel, A.H. (2005). The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nature Medicine. 11 (2), 127-129.

Juliano, R.L. and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455 (1), 152-162.

Kage, K., Tsukahara, S., Sugiyama, T., Asada, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y. (2002). Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer. 97 (5), 626-630.

Kato, Y., Kuwabara, T., Warashina, M., Toda, H., and Taira, K. (2001). Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells. J. Biol. Chem. 276 (18), 15378-15385.

Kawabe, T., Chen, Z.-S., Wada, M., Uchiumi, T., Ono, M., Akiyama, S., and Kuwano, M. (1999). Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Letters. 456 (2), 327-331.

Kelland, L.R. (2000). Preclinical perspectives on platinum resistance. Drugs. 59 (Suppl 4), 1-8.

Kellner, U., Hutchinson, L., Seidel, A., Lage, H., Danks, M.K., Dietel, M., Kaufmann, S.H. (1997). Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-Glycoprotein. Int. J. Cancer. 71 (5), 817-824.

Knutsen, T., Rao, V.K., Ried, T., Mickley, L., Schneider, E., Miyake, K., Ghadimi, B.M., Padilla-Nash, H., Pack, S., Greenberger, L., Cowan, K., Dean, M., Fojo, T., Bates, S. (2000). Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer. 27 (1), 110-116.

Kobayashi, H., Dorai, T., Holland, J.F., and Ohnuma, T. (1994). Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54 (5), 1271-1275.

Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S., Ono, M, and Kuwano, M. (1997). A canalicular multispecific organic anion transporter (cMOAT) Antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57 (24), 5475-5479.

Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F., Borst, P. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57 (16), 3537-3547.

Kowalski, P., Farley, K.M., Lage, H., and Schneider, E. (2004). Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Res. 24 (4, 2231-2236.

Kowalski, P., Stein, U., Scheffer, G.L., and Lage, H. (2002). Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC-transporter BCRP/MXR/ABCG2. Cancer Gene Therapy. 9 (7), 579-586.

Kowalski, P., Surowiak, P., and Lage, H. (2005). Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol. Ther. 11 (4), 508-522.

Kowalski, P., Wichert, A., Holm, P.S., Dietel, M., and Lage, H. (2001). Selection and characterization of a high activity ribozyme directed against the antineoplastic drug resistance-associated ABC-transporter BCRP/MXR/ABCG2. Cancer Gene Therapy. 8 (3), 185-192.

Kruh, G.D. and Belinsky, M.G. (2003). The MRP family of drug efflux pumps. Oncogene. 22 (47), 7537-7552.

Kurreck, J. (2003). Antisense technologies: Improvement through novel chemical modifications.. Eur. J. Biochem.. 270 (8), 1628-1644.

Lage, H and Dietel, M. (2002). Multiple Mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J. Cancer Res. Clin. Oncol. 128 (7), 349-357.

Lage, H., Jordan, A., Scholz, R., Dietel, M. (2000). Thermosensitivity of multidrug-resistant human gastric and pancreatic carcinoma cells. Int. J. Hyperthermia. 16 (4), 291-303.

Lage, H., Perlitz, C., Abele, R., Tampé, R., Dietel, M., Schadendorf, D., Sinha, P. (2001). Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett. 503 (2-3), 179-184.

Lee, C.H. (2004). Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr. Med. Chem. Anti-Canc. Agents. 4 (1), 43-52.

Lee, N.S., Bertrand, E., Rosel, J.J. (1997). Enhancement of ribozyme function by RNA binding proteins. Ribozyme Protocols, Methods in Molecular Biology. 74 Totowa, New Jersey, USA, Humana Press,

Lee, S., Schmitt, C.A. (2003). Chemotherapy response and resistance. Curr. Opin. Genet. Dev. 13 (1), 90-96.

Lepper, E.R., Nooter, K., Verweij, J., Acharya, M.R., Figg, W.D., Sparreboom, A. (2005). Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 6 (2), 115-138.

Licht, T. (1998). Pleiotrope Zytostatikaresistenz (Multidrug Resistance) und Hochdosischemotherapie. Handbuch der Molekularen Medizin. 2 Tumorerkrankungen. (2. Auflage), Springer-Verlag Berlin Heidelberg, 65-87.

Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D.D., Miyake, K., Resau, J.H., Bates, S.E. (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter MXR (ABCG2). J. Cell Sci. 113 (Pt 11), 2011-2021.

Litman, T., Jensen, U., Hansen, A., Covitz, K.M., Zhan, Z., Fetsch, P., Abati, A., Hansen, P.R., Horn, T., Skovsgaard, T., Bates, S.E. (2002). Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim. Biophys. Acta. 1565 (1), 6-16.

Liu, C., Qureshi, I.A., Ding, X., Shan, Y., Huang, Y., Xie, Y., and Ji, M. (1996). Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin. Sci. (Lond.). 91 (1), 93-98.

Liu, Y.Y., Han, T.Y., Giuliano, A.E., Cabot, M.C. (2001). Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15 (3), 719-730.

Liu, Y.Y., Han, T.Y., Giuliano, A.E., Hansen, N., Cabot, M.C. (2000). Uncoupling ceramise glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 275 (10), 7138-7143.

Lotfi, K., Zackrisson, A.L., Peterson, C. (2002). Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett. 178 (2), 141-149.

Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74 (6), 957-967.

Materna, V., Holm, P.S., Dietel, M., and Lage, H. (2001). Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC-transporter cMOAT/MRP2/ABCC3. Cancer Gene Ther. 8 (3), 176-184.

Materna, V., Liedert, B., Thomale, J., Lage, H. (2005). Protection of platinum-DNA-adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer. 115 (3), 393-402.

Mathews, D.H., Disney, M.D., Childs, J.L., Schroeder, S.J., Zuker, M., Turner, D.H. (2004). Incorporating chemical modification constrains into a dynamis programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci USA. 101 (19), 7287-7292.

McManus, M.T. and Sharp, P.A. (2002). Gene silencing in mammals by small interfering RNAs. Nat. Rev. 3 (10), 737-747.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews. 56 (2), 185-229.

Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., Bates, S.E. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res.. 59 (1), 8-13.

Moriyama, M., Hoshida, Y., Otsuka, M., Nishimura, S., Kato, N., Goto, T., Taniguchi, H., Shiratori, Y., Seki, N., Omata, M. (2003). Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol. Cancer Ther. 2 (2), 199-205.

Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65 (1-2), 55-63.

Murray, J.B., Seyhan, A.A., Walter, N.G., Burke, J.M., and Scott, W.G. (1998). The hammerhead, hairpin and VS ribozyme are catalytically proficient in monovalent cations alone. Chem. Biol. 5 (10), 587-595.

Nakagawa, M., Schneider, E., Dixon, K.H., Horton, J., Kelley, K., Morrow, C., Cowan, K.H. (1992). Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52 (22), 6175-6181.

Nedbal, W. and Sczakiel, G. (1997). Hammerhead ribozyme activity in the presence of low molecular weight cellular extract. Antisense Nucleic Acid Drug Dev. 7 (6), 585-589.

Neefjes, J.J., Momburg, F., Hammerling, G.J. (1993). Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science. 261 (5122), 769-771.

Nelson, E.M., Tewey, K.M., Liu, L.F. (1984). Mechanisms of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinyl-amino)-methanesulfon-m-aniside. Proc Natl Acad Sci USA. 81 (5), 1361-1365.

Neumann, H.G. (1992). Chemotherapie von Tumoren. Allgemeine und spezielle Pharmakologie und Toxikologie. (6. Auflage), Wissenschaftsverlag,

Nieth, C. and Lage, H. (2005). Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrp1 (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J Chemother. 17 (2), 215-223.

Nieth, C., Priebsch, A., Stege, A., and Lage, H. (2003). Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545 (2-3), 144-150.

Osada, H., Tokunaga, T., Abe, Y., Asai, S., Miyachi, H., Hatanaka, H., Tsugu, A., Kijima, H., Yamazaki, H., Shima, K., Ueyama, Y., Osamura, Y., Nakamura, M. (2003). Reversal of drug resistance mediated by a hammerhead ribozyme against multidrug resistance-associated protein 1 in a human glioma cell line. Int. J. Oncol. 22 (4), 823-827.

Osheroff, N., Corbett, A.H., Robinson, M. (1994). Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol. 29B 105-126.

Ozvegy, C., Litman, T., Szakacs, G., Nagy, Z., Bates, S., Varadi, A., Sarkadi, B. (2001). Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285 (1), 111-117.

Ozvegy, C., Varadi, A., Sarkadi, B. (2002). Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.. J. Biol. Chem. 277 (50), 47980-47990.

Paolella, G., Sproat, B.S., Lamond, A.I. (1992). Nuclease resistant ribozymes with high catalytic activity. EMBO J. 11 (5), 1913-1919.

Perez, R.P., Godwin, A.K., Handel, A.K., Hamilton, T.C. (1993). A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.. European Journal of Cancer. 29A (3), 395-399.

Perriman, R., Delves, A.G., Gerlach, W.L. (1992). Extended target-side specificity for a hammerhead ribozyme. Gene. 113 (2), 157-163.

Pinto A. L., Lippard, S. J. (1985). Binding of the antitumor drug cis-diamminedichloroplatinum(II)(cisplatin) to DNA. Biochim. Biophys. Acta. 780 (3), 167-180.

Pluen, A., Boucher, Y., Ramanujan, S., McKee, T.D., Gohongi, T., di Tomaso, E., Brown, E.B., Izumi, Y., Campbell, R.B., Berk, D.A., Jain, R.K. (2001). Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. USA. 98 (8), 4628-4633.

Pohl, A., Lage, H., Mueller, P., Pomorski, T., Herrmann, A. (2002). Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem. J. 365 (Pt 1), 259-268.

Prestayko, A.W., D'Aoust, J.C., Issell, B.F., Crooke, S.T. (1979). Cisplatin (cis-diammindichloroplatinumII). Cancer Treat. Rev. 6 (1), 17-39.

Rocchi, E., Khodjakov, A., Volk, E.L., Yang, C.-H., Litman, T., Bates, S.E., Schneider, E. (2000). The product of the ABC half-transporter gene ABCG2 (BCRP,MXR,ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Comm. 271 (1), 42-46.

Ross, D.D., Karp, J.E., Chen, T.T., Doyle, L.A. (2000). Expression of breast cancer resistance in blast cells from patients with acute leukemia. Blood. 96 (1), 365-368.

Ross, D.D., Yang, W., Abruzzo, L.V., Dalton, W.S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S.P., Doyle, L.A. (1999). Atypical multidrug resistance: beast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91 (5), 429-433.

Rossi, J.J. (1992). Ribozymes. Curr. Opin. Biotechnol. 3 (1), 3-7.

Sargent, J.M., Williamson, C.J., Maliepaard, M., Elgie, A.W., Scheper, R.J., Taylor, C.G. (2001). Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br. J. Haematol. 115 (2), 257-262.

Sarkadi, B., Özvegy-Laczka, C., Német, K., Váradi, A. (2004). ABCG2 - a transporter for all seasons. FEBS Letters. 567 (1), 116-120.

Schellens, J.H., Malingre, M.M., Kruijtzer, C.M., Bardelmeijer, H.A., van Tellingen, O., Schinkel, A.H., Beijnen, J.H. (2000). Modulation of oral bioavailability of anticancer drugs: from mouse to man . Eur. J. Pharm. Sci. 12 (2), 103-110.

Scherer, L.J. and Rossi, J.J. (2003). Approaches for the sequence-specific knockdown of mRNA. Nature Biotechnology. 21 (12), 1457-1465.

Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van Deemter, L., Smit, J.J., van der Valk, M.A., Voordouw, A.C., Spits, H., van Tellingen, O., Zijlmans, J.M., Fibbe, W.E., Borst, P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 94 (8), 4028-4033.

Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to an increased sensitivity to drugs. Cell. 77 (4), 491-502.

Shahi, S., and Banerjea, A.C. (2002). Multitarget ribozyme against the S1 genome segment of reovirus possesses novel cleavage activities and is more efficacious than its constituent mono-ribozymes. Antiviral Res. 55 (1), 129-140.

Shimayama, T. Nishikawa, S., Taira, K. (1995). Generality of the NUX rule: Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage side of hammerhead ribozymes.. Biochemistry. 34 (11), 3649-3654.

Siddik, Z.H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22 (47), 7265-7279.

Sigurdsson, S.T., Eckstein, F. (1995). Structure-function relationship of hammerhead ribozymes: from understanding to applications.. Trends Biotechnol.. 13 (8), 286-289.

Skehan, P., Storeng, R., Scudiero, D., Monks, A., Mc Mahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., Boyd, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (13), 1107-1112.

Sparreboom, A., Danesi, R., Ando, Y., Chan, J., Figg, W.D. (2003). Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates. 6 (2), 71-84.

Stage-Zimmermann, T.K. and Uhlenbeck, O.C. (1998). Hammerhead ribozyme kinetics. RNA. 4 (8), 875-889.

Staud, F., Pavek, P. (2005). Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. and Cell. Biol. 37 (4), 720-725.

Stege, A., Priebsch, A., Nieth, C., and Lage, H. (2004). Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interterence. Cancer Gene Ther. 11 (11), 699-706.

Steinbach, D., Lengemann, J., Voigt, A., Hermann, J., Zintl, F., Sauerbrey, A. (2003). Response to Chemotherapy and Expression of the Genes Encoding the Multidrug Resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in Childhood Acute Myeloid Leukemia. Clin. Cancer Res. 9 (3), 1083-1086.

Steinbach, D., Sell, W., Voigt, A., Hermann, J., Sauerbrey, A. (2002). BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia. 16 (8), 1443-1447.

Stephenson, M.L and Zamecnik, P.C. (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA. 75 (1), 285-288.

Stuart, D.D., Kao, G.Y., and Allen, T.M. (2000). A novel, long-circulating , and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther.. 7 (3), 466-475.

Sun, L.Q., Cairns, M.J., Saravolac, E.G., Baker, A., and Gerlach, W.L. (2000). Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52 (3), 325-347.

Surowiak, P., Materna, V., Denkert, C., Kaplenko, I., Spaczynski, M., Dietel, M., Zabel, M., Lage, H. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett.

Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K.J., Reinhold, W., Guo, Y., Kruh, G.D., Reimers, M., Weinstein, J.N., and Gottesman, M.M. (2004). Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell. 6 (2), 129-137.

Taira, K., Nakagawa, K., Nishikawa, S., and Furukawa, K. (1991). Contruction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcription and in vivo as multi-sequences transcription vectors. Nucleic Acids Res. 19 (19), 5125-5130.

Taira, K., Oda, M., Shinshi, H., Maeda, H., and Furukawa, K. (1990). Construction of a novel artificial-ribozyme-releasing plasmid. Protein Engineering. 3 (8), 733-737.

Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., Kuwano, M. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56 (18), 4124-4129.

Taylor, C.W., Dalton, W.S., Parrish, P.R., Gleason, M.C., Bellamy, W.T., Thompson, F.H., Roe, D.J., Trent, J.M. (1991). Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of MCF-7 human breast cancer cell line. Br. J. Cancer. 63 (6), 923-929.

Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G., Stenke, L., Elmhorn-Rosenborg, A., Mollgard, L., Lehman, S., Xu, D., Covelli, A., Gustavsson, B., Paul, C. (2000). P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol. 18. (9), 1837-1844.

Tönnies, H., Poland, J., Sinha, P., Lage, H. (2003). Association of genomic imbalances wih drug resistance and thermoresistance in human gastric carcinoma cells. Int. J. Cancer. 103 (6), 752-758.

Tuschl, T. (2002). Expanding small RNA interference. Nat. Biotechnol. 20 (5), 446-448.

Uhlenbeck, O.C. (2003). Less isn't always more. RNA. 9 (12), 1415-1417.

Usman, N. and Blatt, L.M. (2000). Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106 (10), 1197-1202.

van Herwaarden, A.E., Wagenaar, E., Karnekamp, B., Merino, G., Jonker, J.W., Schinkel, A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemicexposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis.

Wada, M., Toh, S., Taniguchi, K., Nakamura, T., Uchiumi, T., Kohno, K., Yoshida, I., Kimura, A., Sakisaka, S., Adachi, Y., Kuwano, M. (1998). Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemiaII/Dubin-Johnson syndrome. Hum. Mol. Genet. 7 (2), 203-207.

Wani, M.A., Xu, X., Stambrook, P.J. (1994). Increased methotrexate resistance and dhfr amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res. 54 (9), 2504-2508.

Weiss, R.B. (1992). The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol. 19 (6), 670-686.

Wichert, A., Holm, P.S., Dietel, M., Lage, H. (1999). Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using in vitro assay containing total tumor RNA. Cancer Gene Ther. 6 (3), 263-270.

Wichert, A., Stege, A., Midorikawa, Y., Holm, P. S., Lage, H. (2004). Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene. 23 (4), 945-955.

Woehlecke, H., Pohl, A., Alder-Baerens, N., Lage, H., Herrmann, A. (2003). Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem. J. 376 (Pt 2), 489-495.

Wong-Staal, F., Poeschla, E.M., and Looney, D.J. (1998). A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.. Hum. Gene Ther. 9 (16), 2407-2425.

Wu, H., Hait, W.N., and Yang, J.M. (2003). Small interfering RNA-induced suppression of MDR1. Cancer Res.. 63 (7), 1515-1519.

Xu, D., Arestrom, I., Virtala, R., Pisa, P., Peterson, C., Gruber, A. (1999). HIgh levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with interferior response to chemotherapy and prior treatment with mitoxantrone. Br. J. Haematol. 106 (3), 627-633.

Xu, D., Kang, H., Fisher, M., Juliano, R.L. (2004). Strategies for inhibition of MDR1 gene expression. Mol. Pharmacol. 66 (2), 268-275.

Xu, D., McCarty, D., Fernandes, A., Fisher, M., Samulski, R.J., and Juliano, R.L. (2005). Delivery of MDR1 Small Interfering RNA by Self-Complementary Recombinant Adeno-Associated Virus Vector. Mol. Ther. 11 (4), 523-530.

Yagüe, E., Higgins, C.F., and Raguz, S. (2004). Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther. 11 (14), 1170-1174.

Yasui, K., Mihara, S., Zhao, C., Okamoto, H., Saito-Ohara, F., Tomida, A., Funato, T., Yokomizo, A., Naito, S., Imoto, I., Tsuruo, T., and Inazawa, J. (2004). Alterations in copy numbers of genes as a mechanism for aquired drug resistance. Cancer Res. 64. (4), 1403-1410.

Zamecnik, P.C. and Stephenson, M.L. (1978). Inhibition of Rous sarcoma virus by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75 (1), 280-284.

Zeller und zur Hausen (1995). Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen. Loseblattsammlung.

Zoumadakis, M, Tabler, M. (1995). Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucl Acids Res. 23 (7), 1192-1196.

Zuker, M. (1989). On finding all suboptimal foldings of an RNA molecule. Science. 244. (4900), 48-52.

Zuker, M. and Stiegler, P. (1981). Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. 9 (1), 133-148.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
23.08.2006